Print Page  Close Window


SEC Filings

8-K
OREXIGEN THERAPEUTICS, INC. filed this Form 8-K on 05/03/2019
Entire Document
 


Case 18-10518-KG     Doc 1081     Filed 04/29/19     Page 9 of 11

 

In re: Orexigen Therapeutics, Inc.

   Case No. 18-10518 (KG)

Debtor

   Reporting Period: March 1, 2019 - March 31, 2019

 

MOR -3

Balance Sheet

(Unaudited)

 

     Orexigen Therapeutics, Inc.      
$ USD ‘000s    As of March 11, 2018      As of March 31, 2019      

 

Assets

       

    Current assets:

       

      Cash and cash equivalents

     $ 21,372          $ 25,157      

      Accounts receivable, net

     19,203          -      

      Inventory

     8,857          -      

      Prepaid expenses and other current assets

     6,868          6,563      

      Intercompany receivab1e(1)

     93,353          -      
  

 

 

    

 

 

   

    Total current assets

     149,653          31,720      

    Non-current assets:

       

      Property and equipment, net

     543          -      

      Investment in Subsidiary(1)

     19,000          -      

      Intangible assets

     66,566          0      

      Other long-term assets

     588          1,252      

      Restricted cash

     100          100      
  

 

 

    

 

 

   

Total assets

     $ 236,450          $ 33,072      
  

 

 

    

 

 

   

Liabilities and Stockholders’ Equity

       

    Current liabilities:

       

      Accounts payable(2)

     925          705      

      DIP loan

     -          -      

      Accrued expenses

     3,921          7,314      
  

 

 

    

 

 

   

    Total current liabilities:

     4,846          8,019      
  

 

 

    

 

 

   

    Total liabilities not subject to compromise

     4,846          8,019      

    Total liabilities subject to compromise

     110,381          244,550      

    Series Z preferred stock

     3,343          -      

Stockholders’ equity (deficit)

     117,880          (219,497)      
  

 

 

    

 

 

   

Total liabilities and stockholders’ equity (deficit)

     $ 236,450          $ 33,072      
  

 

 

    

 

 

   

Notes:

 

(1) Investment in Subsidiary $19m reclassed from Intercompany Receivable at March 11 , 2018 to properly align for reporting.

(2) Accounts payable excludes all liabilities assumed by the purchaser under the terms of the Asset Purchase Agreement.